Slide 1: Third Quarter 2022 Operating & Financial Results Conference Call / Webinar
Third Quarter 2022 Operating & Financial Results Conference Call / Webinar November 7th, 2022 4:30 PM Eastern Time NASDAQ :LTRN
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements r
Slide 3: Contents, Speakers, Host
Contents Speakers Host 01 Introduction 02 Q3 2022 Highlights Panna Sharma Chief Executive Officer, President and Director 03 Financial Highlights 04 Q&A David Margrave Nicole Leber Chief Financial Officer Investor Relations 2
Slide 4: Using A.I. Lantern is Transforming Drug Discovery Timelines and Cost
Using A.I. Lantern is Transforming Drug Discovery Timelines and Cost Lantern has launched 8 programs in two years, and is anticipating launching 3 Phase 1 trials in 2023 Lantern’s Drug Development Model Large Scale/Multi-omics Proprietary A.I. Accelerated timeline Oncology Data platform RADR® and re
Slide 5: Third Quarter 2022 Highlights
Third Quarter 2022 Highlights LP-300 and Harmonic™ Trial RADR® Expansion • Activated first two clinical trial sites • RADR® continues rapid data growth & advances in • First enrolled patients anticipated in Q4 2022 functionality • New patent issued for LP-300 uses • Actuate collaboration progressing
Slide 6: The Harmonic Trial for Never Smoker Patients with NSCLC
The Harmonic™ Trial for Never Smoker Patients with NSCLC Harmonic™ for LP-300 launched in Q3 2022 and is actively enrolling trial sites and patients Primary Outcomes: Overall and progression free survival 1st patient Interim Results Additional Value Drivers Q4 Q4 2022 Enrollment anticipated to last
Slide 7: LP-184 has Potent Efficacy Across Multiple Solid Tumors and CNS Cancers
LP-184 has Potent Efficacy Across Multiple Solid Tumors and CNS Cancers Across all programs LP-184 has the potential to be valued at over $6 billion Solid Tumors Program Highlights • Pancreatic Cancer • Unique Mechanism of Action: • Bladder Cancer • Synthetic lethality • Overexpression of PTGR1 • Brea
Slide 8: First-in-human Phase 1 Clinical Trials are Anticipated in Early 2023 for LP-184
First-in-human Phase 1 Clinical Trials are Anticipated in Early 2023 for LP-184 World-class collaborators have accelerated the path towards first-in-human clinical trials LP-184 Phase 1 Trials in 2023* *Anticipated Timeline Q4 2022 Q1 2023 Q2 2023 Solid Tumors Complete IND enabling studies and file
Slide 9: Lantern's CNS Programs have Multi-Billion Dollar Stand-Alone Potential
Lantern‘s CNS Programs have Multi-Billion Dollar Stand-Alone Potential LP-184 has hallmark molecular characteristics for development in CNS cancers Total Market Potential* CNS Indications and programs in CNS Cancers Indication Program R&D Preclinical Phase I $5+ Billion Glioblastoma LP-184 Brain Met
Slide 10: LP-184 has a Unique Mechanism of Action Leveraging Synthetic Lethality
LP-184 has a Unique Mechanism of Action Leveraging Synthetic Lethality Genetic factors contributing to LP-184's Synthetic Lethality Synthetic Lethality for LP-184 KOL Webinar on Synthetic Lethality Dr. Zoltan Szallasi, M.D. Principal investigator at Danish Cancer Society Research Center Assistant Pr
Slide 11: LP-284 was Developed from RADR Insights to Late-Stage IND Enabling Studies
LP-284 was Developed from RADR® Insights to Late-Stage IND Enabling Studies in Less Than 2 Years for Non-Hodgkin’s Lymphomas LP-284 for non-Hodgkin’s B-cell lymphomas Current Market Size of Mantle Cell & Double Hit Lymphomas • Mantle Cell Lymphoma $1.0 Billion Annual US Cases 5K • Double Hit Lymphom
Slide 12: RADR is Lantern's A.I. and M.L. Platform that Powers Oncology Drug Discovery
RADR® is Lantern’s A.I. and M.L. Platform that Powers Oncology Drug Discovery and Development Response Algorithm for Drug Positioning & Rescue A proprietary integrated data analytics, experimental biology, oncology-focused, machine- learning-based platform focused on drug development 80%+ Leverages
Slide 13: Lantern's Collaborators are Leveraging RADR to Accelerate Their Drug Development
Lantern’s Collaborators are Leveraging RADR® to Accelerate Their Drug Development Actuate Therapeutics is actively applying RADR® insights for Phase 2 development of its drug candidate elraglusib Actuate Therapeutics, Inc. is a private clinical stage biopharmaceutical company focused on the developm
Slide 14: Recent and Upcoming Publications and Posters Highlighting Validation of RADR Insights
Recent and Upcoming Publications and Posters Highlighting the Strong Validation of RADR® Insights, De-risking the Development of Lantern’s Drug Candidates Recent Posters/ Publications Upcoming Scientific Conferences Society of Neuro Oncology Annual Meeting Tampa, FL Nov. 16-20, 2022 LP-184, a tumor
Slide 15: Financial Updates Q3 2022
Financial Updates Q3 2022 Solid financial position and capital efficiency fuel continued growth and give Lantern cash runway into 2025 Summary Results of Operations Balance Sheet Highlights & Summary Three Months Ended September 30, (unaudited) (unaudited) 2022 2021 9/30/2022 12/31/2021 Operating ex
Slide 16: 2022-23 Objectives
2022-23 Objectives A Transformational year for Lantern ● Advance enrollment of The Harmonic™ Trial & increase patient/clinician awareness ● Finalize IND-Enabling studies & clinical trial design for LP-184 ● Design Ph. 2 clinical trial for LP-184 in GBM ● Progress LP-184 towards Ph. 1 / 2 pediatric c
Slide 17: Connect With Us
IR Contact: IR@lanternpharma.com 1-972-277-1136 Nasdaq: LTRN www.lanternpharma.com @LanternPharma CONNECT WITH US Third Quarter 2022 Earnings